Yaping Wang

Has grant

Assistant Professor

Virginia Commonwealth University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

VCU Commercialization Fund

Open Date: 2026-07-01

Close Date: 2027-06-01

Grant: Close

Richmond VAMC/RIVR Pilot Grant

Open Date: 2025-02-01

Close Date: 2026-08-01

Articles (7)

Year:

2025

Year:

2025

Year:

2025

Larsucosterol, a potent endogenous epigenetic regulator, has been reported to play a significant role in lipid metabolism, inflammatory responses, and cell survival. The administration of larsucosterol has demonstrated a reduction in lipid accumulation within hepatocytes and the attenuation of inflammatory responses induced by lipopolysaccharide (LPS) and TNFα in macrophages, alleviating LPS- and acetaminophen (ATMP)-induced multiple organ injury, and decreasing mortalities in animal models. Results from phase 1 and 2 clinical trials have shown that larsucosterol has potential as a biomedicine for the treatment of acute and chronic liver diseases. Recent evidence suggests that larsucosterol is a promising candidate for treating alcohol-associated hepatitis with positive results from a phase 2a clinical trial, and for metabolic dysfunction-associated steatohepatitis (MASH) from a phase 1b clinical trial. In this review, we present a culmination of our recent research efforts spanning two decades. We summarize the discovery, physiological and pharmacological mechanisms, and clinical applications of larsucosterol. Furthermore, we elucidate the pathophysiological pathways of metabolic dysfunction-associated steatotic liver diseases (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and acute liver injuries. A central focus of the review is the exploration of the therapeutic potential of larsucosterol in treating life-threatening conditions, including acetaminophen overdose, endotoxin shock, MASLD, MASH, hepatectomy, and alcoholic hepatitis.

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (3)

Genta Kakiyama

Associate Professor

University of Virginia School of Medicine

UNITED STATES
View details

William Pandak

Professor of Medicine

Virginia Commonwealth University

UNITED STATES
View details

Shunlin Ren

Virginia Commonwealth University

UNITED STATES
View details